STE
STERIS plc
NYSE · Healthcare · Medical - Devices · IE
$225.16
−0.74%Year over year
Reported trailing growth
- Revenue
- +8.4%
- EBITDA
- +28.6%
- EBIT
- +23.1%
- EPS
- +25.0%
- Free cash flow
- +1.8%
- Operating cash flow
- +1.9%
Forward estimates
Based on analyst estimates
- Revenue
- +7.2%
- EBITDA
- -2.1%
- EPS
- +39.9%
Three-year CAGR
- Revenue
- +9.4%
- EBITDA
- +8.9%
- EBIT
- +11.7%
- Net income
- +94.3%
- EPS
- +95.0%
- Free cash flow
- +35.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026